Collplant Holdings (CLGN)
NASDAQ:CLGN
Want to see CLGN full AI Analyst Report?
Top Page
Collplant Holdings
(NASDAQ:CLGN)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.38
▼(-74.57% Downside)
Action:Reiterated
Date:05/30/26
The score is primarily constrained by weak financial performance, driven by steep revenue contraction, sizable ongoing losses, and continued cash burn. Technicals also weigh on the score due to a clear downtrend versus key moving averages, while valuation provides limited support because the company is loss-making and has no stated dividend yield.
Positive Factors
Proprietary rhCollagen IP
Established patent protection across key markets for photocurable fillers and Collink.3D bioinks supports durable competitive differentiation. Strong IP lowers imitation risk, facilitates licensing or partner deals, and underpins long-term revenue potential from collagen-based platforms and bioinks.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow indicates the business remains dependent on external financing. Continued cash burn constrains R&D, manufacturing scale-up, and commercialization without new funding or timely partner payments, raising dilution and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary rhCollagen IP
Established patent protection across key markets for photocurable fillers and Collink.3D bioinks supports durable competitive differentiation. Strong IP lowers imitation risk, facilitates licensing or partner deals, and underpins long-term revenue potential from collagen-based platforms and bioinks.
Read all positive factors
Collplant Holdings (CLGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.69M
Dividend YieldN/A
Average Volume (3M)29.18K
Price to Earnings (P/E)―
Beta (1Y)-0.04
Revenue Growth-84.26%
EPS Growth14.73%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.03
Shares Outstanding14,415,128
10 Day Avg. Volume15,198
30 Day Avg. Volume29,183
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.81
Price to Sales (P/S)7.21
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue8.48
Enterprise Value/Gross Profit-2.66
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$2.00M
Collplant Holdings Business Overview & Revenue Model
Company Description
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombin...
How the Company Makes Money
CollPlant makes money primarily by monetizing its proprietary rhCollagen technology platform through (1) collaboration and development agreements, (2) licensing and related intellectual property (IP) payments, and (3) sales of collagen-based produ...
Collplant Holdings Earnings Call Summary
Earnings Call Date:Mar 26, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Positive Updates
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Negative Updates
Significant Revenue Decline
Revenue for the year ended December 31, 2024, was $515,000, a sharp decrease from $11 million in 2023, mainly due to a $10 million milestone payment in 2023 not repeated in 2024.
Read all updates
Q4-2024 Updates
Positive
Negative
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Read all positive updates
Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.Collplant Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 389.00K | 2.37M | 515.00K | 10.96M | 299.00K | 15.64M |
| Gross Profit | -1.24M | 624.00K | -2.15M | 7.87M | -1.18M | 13.64M |
| EBITDA | -12.05M | -10.57M | -15.55M | -5.91M | -15.81M | 1.05M |
| Net Income | -13.13M | -11.49M | -16.61M | -7.02M | -16.93M | 237.00K |
Balance Sheet | ||||||
| Total Assets | 9.18M | 10.79M | 18.71M | 34.13M | 37.77M | 51.22M |
| Cash, Cash Equivalents and Short-Term Investments | 4.26M | 5.95M | 11.91M | 26.67M | 29.65M | 43.30M |
| Total Debt | 2.65M | 2.85M | 3.08M | 3.16M | 2.91M | 3.61M |
| Total Liabilities | 4.30M | 4.70M | 5.25M | 5.79M | 5.49M | 6.10M |
| Stockholders Equity | 4.89M | 6.08M | 13.46M | 28.34M | 32.28M | 45.12M |
Cash Flow | ||||||
| Free Cash Flow | -11.60M | -9.45M | -14.58M | -3.72M | -14.97M | 1.07M |
| Operating Cash Flow | -11.58M | -9.42M | -14.09M | -2.76M | -13.70M | 2.50M |
| Investing Cash Flow | -26.09K | -27.00K | -539.00K | -1.16M | 28.92M | -31.56M |
| Financing Cash Flow | 4.87M | 3.10M | 9.00K | 1.11M | 1.87M | 38.76M |
Collplant Holdings Technical Analysis
Negative
1.51
Price Trends
0.41
Negative
0.70
Negative
1.44
Negative
Market Momentum
-0.01
Positive
37.86
Neutral
9.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 1.51 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.41, and above the 200-day MA of 1.44, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 37.86 is Neutral, neither overbought nor oversold. The STOCH value of 9.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.
Collplant Holdings Risk Analysis
Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Collplant Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $92.17M | -2.93 | -241.96% | ― | ― | 55.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $265.33M | -454.35 | -0.29% | ― | -100.00% | 72.96% | |
45 Neutral | $32.66M | -2.27 | 763.44% | ― | ― | ― | |
44 Neutral | $27.58M | -2.93 | 9999.00% | ― | ― | ― | |
42 Neutral | $19.25M | -0.48 | -135.04% | ― | ― | 42.29% | |
41 Neutral | $5.69M | -0.39 | -92.74% | ― | -84.26% | 14.73% |
* Healthcare Sector Average
CLGN
Collplant Holdings
0.37
-1.57
-80.88%
DARE
Daré Bioscience
1.88
-1.32
-41.25%
PASG
Passage Bio
5.62
-2.84
-33.57%
PYPD
PolyPid
4.50
1.23
37.61%
SABS
SAB Biotherapeutics
3.38
1.57
86.74%
NRSN
Neurosense Therapeutics Ltd.
0.75
-1.04
-58.10%
Collplant Holdings Corporate Events
CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline
May 29, 2026
On May 29, 2026, CollPlant Biotechnologies reported first-quarter 2026 results and said it has begun talks with several leading industry players on potential collaborations for next-generation dermal fillers that combine its rhCollagen with hyalur...
CollPlant Resets Strategy After AbbVie Ends Filler Deal, Slashes Workforce by 50%
Apr 13, 2026
On April 9, 2026, Allergan Industrie SAS, an AbbVie company, notified CollPlant that it would terminate their February 2021 development agreement for an rhCollagen-based dermal and soft tissue filler, with the collaboration to end on June 8, 2026....
CollPlant Biotechnologies Details 2025 Results, Bioprinting Launch and Regenerative Implant Progress
Mar 26, 2026
On March 26, 2026, CollPlant Biotechnologies reported its 2025 financial results and outlined a broad corporate update highlighting progress in aesthetics, 3D bioprinting, and regenerative implants. The company emphasized a development milestone i...
CollPlant Biotechnologies Faces Nasdaq Bid-Price Deficiency, Granted Compliance Window
Mar 24, 2026
On March 23, 2026, CollPlant Biotechnologies received a Nasdaq notice that its ordinary shares had closed below $1.00 for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5550(a)(2). Under Nasdaq rules, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.